Interdisciplinary management of skin cancer.

The interdisciplinary treatment of skin cancer in the head and neck area requires close collaboration between different specialist disciplines. The most common non-melanoma skin cancer tumor entities are cutaneous squamous cell carcinoma and basal cell carcinoma as well as their precursor lesions. One of the less common tumors is Merkel cell carcinoma, which also occurs primarily in light-exposed areas and, in contrast to squamous and basal cell carcinoma, is more likely to metastasize. Due to the low tendency of basal cell carcinoma as well as cutaneous squamous cell carcinoma to metastasize, a cure can often be achieved by surgery. If the tumor growth exceeds certain levels it may require collaboration between dermatology and otorhinolaryngology. The primary goal of this interdisciplinary collaboration is to achieve a functional, cosmetically and aesthetically acceptable result in addition to adequate tumor treatment. Depending on the stage of the tumor and the clinical course, a case may be discussed in an interdisciplinary tumor board in order to determine a personalised, appropriate and adequate treatment concept for each patient, including prevention, therapy and follow-up. Die interdisziplinäre Behandlung von Hautkrebs im Kopf-Halsbereich erfordert die enge Zusammenarbeit zwischen verschiedenen Fachdisziplinen. Die häufigsten nicht-melanozytären Tumorentitäten sind das kutane Plattenepithelkarzinom und das Basalzellkarzinom sowie deren Vorläuferläsionen. Zu den eher selteneren Tumoren gehört das Merkelzellkarzinom, welches ebenfalls vornehmlich an den lichtexponierten Arealen auftritt und im Gegensatz zum Platten- und Basalzellkarzinom häufiger eine Metastasierung aufweist. Aufgrund der geringen Tendenz des Basalzellkarzinoms wie auch des kutanen Plattenepithelkarzinoms zur Metastasierung, kann eine Kuration häufig durch eine Operation erreicht werden. Überschreitet hier das Tumorwachstum entsprechende Grenzen kann eine Zusammenarbeit zwischen Dermatologie und HNO erforderlich sein. Das primäre Ziel dieser interdisziplinären Zusammenarbeit ist, neben dem Erreichen der Tumorfreiheit, ein funktionell sowie kosmetisch-ästhetisch ansprechendes Ergebnis. In Abhängigkeit von Tumorstadium und Klinik ist eine Vorstellung in der interdisziplinären Tumorkonferenz zu empfehlen, um ein vollumfängliches und fachlich adäquates sowie Patienten-individuelles Therapiekonzept festzulegen, welches die Bausteine Prävention, Therapie und Nachsorge eines jeden Patienten umfasst.

Informations de copyright

The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Déclaration de conflit d'intérêts

Dres. Eisenburger, Leven und Rudolph erklären keine Interessenkonflikte zu haben. Prof. Schadendorf erklärt verschiedene Interessenkonflikte zu haben: Anaveon, Advisory Board, Personal AstraZeneca, Expert Testimony, Personal BioAlta, Expert Testimony, Personal BioNTech, Advisory Board, Personal BMS, Invited Speaker, Personal BMS, Advisory Board, Personal CureVac, Advisory Board, Personal Daiichi Sanyko, Expert Testimony, Personal Erasca, Advisory Board, Personal Formycon, Expert Testimony, Personal Immatics, Advisory Board, Personal Immunocore, Advisory Board, Personal InFlarX, Expert Testimony, Personal Merck Serono, Invited Speaker, Personal MSD, Invited Speaker, Personal MSD, Advisory Board, Personal Neracare, Advisory Board, Personal Neracare, Invited Speaker, Personal Novartis, Advisory Board, Personal NoviGenix, Advisory Board, Personal PamGene, Expert Testimony, Personal Pfizer, Advisory Board, Personal Philogen, Advisory Board, Personal Pierre Fabre, Advisory Board, Personal Replimune, Advisory Board, Personal Sanofi, Invited Speaker, Personal Sanofi/Regeneron, Advisory Board, Personal Seagen, Expert Testimony, Personal SunPharma, Advisory Board, Personal SunPharma, Invited Speaker, Personal Ultimovacs, Advisory Board, Personal BMS, Coordinating PI, Institutional, No financial interest BMS, Steering Committee Member, Personal, Financial interest BMS, Research Grant, Institutional, Financial interest MSD, Coordinating PI, Institutional, No financial interest MSD, Research Grant, Institutional, Financial interest MSD, Steering Committee Member, Personal, Financial interest Novartis, Coordinating PI, Institutional, No financial interest Novartis, Steering Committee Member, Personal, No financial interest Philogen, Local PI, Institutional, No financial interest Pierre Fabre, Coordinating PI, Institutional, No financial interest Sanofi, Local PI, Institutional, No financial interest Non-Financial Interests EORTC-MG, Member of Board of Directors European Melanoma Registry (EuMelaReg), Leadership Role, Founding member and SC chair Prof. Wiegand gibt an: Wissenschaftliche Präsentationen / Teilnahme an Advisory Boards / Kongressunterstützung; Astra Zeneca, Bristol-Myers Squibb, GSK, Merck Serono, MSD, Roche, Sanofi, Genzyme